Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis

NCT00755456 is registered in ClinicalTrials.gov with Iperboreal Pharma Srl as lead sponsor.

NCT NCT00755456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00755456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis
Lead sponsor
Iperboreal Pharma Srl
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
October 31, 2012
Enrollment
35 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, insulin resistance